4568.T

Daiichi Sankyo Company, Limited [4568.T] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

4568.T Stock Summary

Earnings have grown 22.36% per last year.

Earnings are expected to fall -100% next year

4568.T has less than 1 year of cash runway

Top 10 Correlated ETFs

4568.T

Top 10 Correlated Stocks

4568.T

In the News

4568.T Financial details

Company Rating

Strong Buy

Market Cap

8881.62B

Income

186.05B

Revenue

1503.47B

Book val./share

827.32

Cash/share

626.36

Dividend

Dividend %

0.74%

Employees

17.44K

Optionable

Shortable

Yes

Earnings

25 Apr 2024

P/E

56.17

Forward P/E

PEG

3.16

P/S

5.95

P/B

5.21

P/C

7.37

P/FCF

-104.38

Quick Ratio

2.06

Current Ratio

2.86

Debt / Equity

0.07

LT Debt / Equity

0.06

EPS (TTM)

97.04

EPS next Y

EPS next Q

EPS this Y

63.02%

EPS next Y

EPS next 5Y

EPS last 5Y

3.45%

Revenue last 5Y

6.58%

Revenue Q/Q

19.02%

EPS Q/Q

66.4%

SMA20

-5.41%

SMA50

2.21%

SMA100

13.26%

Inst Own

Inst Trans

ROA

ROE

10%

ROC

0.06%

Gross Margin

72%

Oper. Margin

Profit Margin

11%

Payout

39%

Shs Outstand

Shs Float

Target Price

52W Range

3566.0-5173.0

52W High

-10.81%

52W Low

+29.39%

RSI

Rel Volume

0.78

Avg Volume

4.15M

Volume

3.22M

Perf Week

1.88%

Perf Month

-4.61%

Perf Quarter

9.47%

Perf Half Y

14.35%

Beta

0.293

Volatility

57.38%, 140.23%

Prev Close

1.72%

Price

4614

Change

2.67%

4568.T Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	478.41	505.08	496.31	545.18	666.9
Net income per share	48.07	66.4	39.17	34.94	56.96
Operating cash flow per share	47.36	101.14	99.11	72.64	59.73
Free cash flow per share	13.08	74.1	66.06	32.63	24.59
Cash per share	401.39	458.22	425.36	440.28	430.42
Book value per share	643.03	671.77	655.92	704.83	754.21
Tangible book value per share	515.8	543.78	526.74	575.72	619.66
Share holders equity per share	643.03	671.77	655.92	704.83	754.21
Interest debt per share	137.31	119.36	96.21	88.29	79.06
Market cap	3576.41B	4816.84B	6254.38B	5136.49B	9243.94B
Enterprise value	3594.19B	4616.85B	6057.67B	4637.48B	8945.1B
P/E ratio	38.29	37.32	82.34	76.7	84.66
Price to sales ratio	3.85	4.91	6.5	4.92	7.23
POCF ratio	38.86	24.5	32.54	36.89	80.72
PFCF ratio	140.69	33.44	48.82	82.13	196.06
P/B Ratio	2.86	3.69	4.92	3.8	6.39
PTB ratio	2.86	3.69	4.92	3.8	6.39
EV to sales	3.87	4.7	6.29	4.44	7
Enterprise value over EBITDA	26.06	22.9	45.12	33.72	44.04
EV to operating cash flow	39.05	23.48	31.52	33.31	78.11
EV to free cash flow	141.39	32.05	47.28	74.15	189.72
Earnings yield	0.03	0.03	0.01	0.01	0.01
Free cash flow yield	0.01	0.03	0.02	0.01	0.01
Debt to equity	0.21	0.17	0.14	0.12	0.1
Debt to assets	0.12	0.11	0.09	0.07	0.06
Net debt to EBITDA	0.13	-0.99	-1.47	-3.63	-1.47
Current ratio	3.62	3.94	3.59	3.4	2.82
Interest coverage	14.16	17.77	23.16	12.69	14.22
Income quality	1.07	1.39	2.59	1.89	0.9
Dividend Yield	0.01	0.01	0.01	0.01	0.01
Payout ratio	0.49	0.35	0.64	0.77	0.5
Sales general and administrative to revenue	0.3	0.31	0.35	0.34	0.37
Research and developement to revenue	0.22	0.2	0.24	0.25	0.27
Intangibles to total assets	0.12	0.12	0.12	0.11	0.1
Capex to operating cash flow	-0.72	-0.27	-0.33	-0.55	-0.59
Capex to revenue	-0.07	-0.05	-0.07	-0.07	-0.05
Capex to depreciation	-1.44	-1	-1.12	-1.32	-0.99
Stock based compensation to revenue	0	0	0	0	0
Graham number	833.92	1K	760.28	744.41	983.13
ROIC	0.06	0.08	0.04	0.04	0.06
Return on tangible assets	0.05	0.07	0.04	0.03	0.05
Graham Net	178.01	211.01	147.6	147.28	91.15
Working capital	1008.64B	1033.05B	914.85B	950B	964.79B
Tangible asset value	1002.38B	1057.02B	1021.53B	1103.43B	1187.92B
Net current asset value	554.84B	584.77B	455.3B	474.74B	432.02B
Invested capital	0.21	0.17	0.14	0.12	0.1
Average receivables	326.57B	365.55B	270.77B	249.36B	307.89B
Average payables	269.41B	291.76B	284.18B	311.14B	374.41B
Average inventory	174.33B	174.71B	187.11B	209.39B	259.76B
Days sales outstanding	165.52	115.06	87.99	93.15	99.67
Days payables outstanding	313	288.07	320.99	335.51	425.76
Days of inventory on hand	176.26	184.37	216.72	225.11	302.83
Receivables turnover	2.21	3.17	4.15	3.92	3.66
Payables turnover	1.17	1.27	1.14	1.09	0.86
Inventory turnover	2.07	1.98	1.68	1.62	1.21
ROE	0.07	0.1	0.06	0.05	0.08
Capex per share	-34.28	-27.04	-33.05	-40.01	-35.14

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	177.6	172.22	182.98	195.84	233.08
Net income per share	14.81	11.73	29.74	20.86	34.71
Operating cash flow per share	18.79	16.89	-24.12	-9.46	330.48
Free cash flow per share	9.62	8.14	-37.94	-21.32	316.83
Cash per share	414.78	430.35	386.38	348.54	626.36
Book value per share	737.73	754.09	797.91	831.32	827.32
Tangible book value per share	592.7	619.56	662.03	694.04	696.56
Share holders equity per share	737.73	754.09	797.91	831.32	827.32
Interest debt per share	75.86	74.45	82.29	62.74	65.57
Market cap	8147.79B	9245.43B	8723.92B	7872.98B	7424.38B
Enterprise value	7895.79B	8946.6B	8361.31B	7396.58B	6871.87B
P/E ratio	71.75	102.78	38.25	49.21	27.89
Price to sales ratio	23.93	28	24.87	20.97	16.61
POCF ratio	226.13	285.55	-188.67	-433.87	11.72
PFCF ratio	441.71	592.39	-119.92	-192.55	12.22
P/B Ratio	5.76	6.39	5.7	4.94	4.68
PTB ratio	5.76	6.39	5.7	4.94	4.68
EV to sales	23.19	27.09	23.83	19.7	15.38
Enterprise value over EBITDA	144.81	430.56	124.74	105.23	55.32
EV to operating cash flow	219.14	276.32	-180.83	-407.62	10.84
EV to free cash flow	428.05	573.24	-114.94	-180.89	11.31
Earnings yield	0	0	0.01	0.01	0.01
Free cash flow yield	0	0	-0.01	-0.01	0.08
Debt to equity	0.1	0.1	0.1	0.07	0.07
Debt to assets	0.06	0.06	0.06	0.04	0.03
Net debt to EBITDA	-4.62	-14.38	-5.41	-6.78	-4.45
Current ratio	3.15	2.82	2.74	2.86	3.49
Interest coverage	14.05	19.61	60.57	8.6	8.65
Income quality	1	-54.33	-0.89	-0.36	6.48
Dividend Yield	0	0	0	0	0.01
Payout ratio	1.01	0	0.51	0	0.58
Sales general and administrative to revenue	0.36	0.43	0.39	0.38	0.36
Research and developement to revenue	0.26	0.31	0.22	0.24	0.2
Intangibles to total assets	0.12	0.1	0.1	0.1	0.08
Capex to operating cash flow	-0.49	-0.52	0.57	1.25	-0.04
Capex to revenue	-0.05	-0.05	-0.08	-0.06	-0.06
Capex to depreciation	-1.09	-0.77	-1.87	-1.58	-1.75
Stock based compensation to revenue	0	0	0	0	0
Graham number	495.8	446.1	730.64	624.61	803.83
ROIC	0.02	0.15	0.03	0.02	0.04
Return on tangible assets	0.01	0.01	0.02	0.02	0.02
Graham Net	110.65	91.13	68.11	64.76	37.79
Working capital	980.54B	964.79B	957.18B	991.48B	1510.76B
Tangible asset value	1136.28B	1187.92B	1269.34B	1330.77B	1335.63B
Net current asset value	453.9B	432.02B	422.37B	468.63B	435.74B
Invested capital	0.1	0.1	0.1	0.07	0.07
Average receivables	344.95B	352.76B	378.76B	418.98B	453.21B
Average payables	345.3B	391.21B	427.71B	449.77B	462.21B
Average inventory	264.41B	284.15B	320.44B	358.45B	384.43B
Days sales outstanding	94.21	95.15	104.77	102.95	96.03
Days payables outstanding	329.21	360.09	414.46	444.75	335.64
Days of inventory on hand	244.98	256.12	325.96	358.75	287.8
Receivables turnover	0.96	0.95	0.86	0.87	0.94
Payables turnover	0.27	0.25	0.22	0.2	0.27
Inventory turnover	0.37	0.35	0.28	0.25	0.31
ROE	0.02	0.02	0.04	0.03	0.04
Capex per share	-9.17	-8.75	-13.82	-11.86	-13.65

4568.T Dividend History

4568.T Frequently Asked Questions

What is Daiichi Sankyo Company, Limited stock symbol ?

Daiichi Sankyo Company, Limited is a JP stock and trading under the symbol 4568.T

What is Daiichi Sankyo Company, Limited stock quote today ?

Daiichi Sankyo Company, Limited stock price is $4614 today.

Is Daiichi Sankyo Company, Limited stock public?

Yes, Daiichi Sankyo Company, Limited is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 4.15M
Market Capitalization 8881.62B
Employee 17.44K
CEO Mr. Sunao Manabe D.V.M., Ph.D.
Headquarters Tokyo,JP
IPO Date 2000-01-04
Website https://www.daiichisankyo.com

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.